2024 ATS Conference News Preview - 17

CONFERENCE PREVIEW EDITION
17
Respiratory Innovation Summit Connects Global Industry
Leaders and Innovators Advancing Respiratory Health
E
ach year, the ATS unites
innovators, investors,
clinicians, and advocacy
groups who are leading the
efforts to develop powerful
new treatments for deadly and
crippling diseases of the lungs and
airways at the annual Respiratory
Innovation Summit. The 2024 RIS
will be hosted on Friday, May 17, and
Saturday, May 18, at the Manchester
Grand Hyatt San Diego.
This meeting historically attracts
more than 375 global leaders
representing all facets of the
respiratory industry, including
representatives from start-ups,
business development, venture
capital, government, academia, and
clinical medicine. All companies
innovating in pulmonary, critical
care, or sleep medicine are
encouraged to apply.
" Lassen is a small company, so
any venue
where we
can share
our program
data with
the broader
pharma,
biotech, and
investor
community
is incredibly
beneficial
for us, "
said Lassen
Therapeutics
Vice President
of Fibrosis and
Translational Biology and former
RIS participant Jamie Swaney,
PhD. " The RIS has been great in
providing this level of increased
exposure for our company. Aside
from the business development
benefits, RIS always assembles
the best-of-the-best in terms of
industry and academic leaders in
the pulmonary field, so the level of
scientific discussion and feedback
is top-notch. "
The planning committee will select
75 companies to be featured for poster
presentations. Among the 75 selected
organizations, 20 will be spotlighted for
six-minute oral presentations. The RIS
agenda also includes a venture capital
panel, angel investor panel, business
development panel, and plenty of time
for networking.
" RIS provided a unique opportunity
Aside from the business
development benefits, RIS
always assembles the best-ofthe-best
in terms of industry
and academic leaders in the
pulmonary field, so the level
of scientific discussion and
feedback is top-notch. "
Jamie Swaney, PhD, Lassen Therapeutics
Vice President of Fibrosis and Translational
Biology and former RIS participant
for Apnimed to showcase our clinical
program of research to a diverse
audience, " explained Apnimed Senior
Vice President of Clinical Development
and previous RIS participant John
Cronin, MD. " We are developing a
first-in-class
therapeutic, so it
is critical for us
to articulate our
mission, science,
and vision. We
received valuable
feedback from
a variety of
scientists,
pharmaceutical
executives, and
VCs. "
RIS registrants
will be invited
to attend a
networking
reception and dinner with a keynote
address on Friday. On Saturday, the
program will include a full day of
programming, continental breakfast,
lunch, dedicated
networking time,
and a closing
reception.
The full
agenda for the
meeting can
be found on
the conference
website,
conference.
thoracic.org.
The summit is a non-CME
program.
RIS registration is located
in the same system as ATS
2024 International Conference
registration, either as a single
event or as an additional fee to
overall ATS 2024 registration.
RIS attendance does not include
or require full registration for
ATS 2024, but attendees are
encouraged to be a part of
the larger ATS community. RIS
John Cronin, MD
Jamie Swaney, PhD
attendees are encouraged to take
advantage of the hotel blocks
offered during the event.
The ATS gratefully acknowledges
the members of the RIS Advisory
Board and Planning Committee,
who donated their time to develop
this pioneering event.
To secure or inquire about
sponsorship opportunities at the
RIS or learn more about the
RIS, contact Dustin Bell at
dbell@thoracic.org.
Sunday, May 19 │ 11:35 - 11:55 a.m. PDT │ Innovation Hub 3 (Booth #1855)
Chiesi Innovation Hub:
Silent No More - Uncovering the Role of Small
Airways in Asthma
Join us for an expert led Innovation Hub focused on understanding
small airway dysfunction and persistent airflow limitation in asthma.
Presented By:
Monica Kraft, MD
Murray M. Rosenberg Professor of
Medicine and System Chair
Department of Medicine at Mount
Sinai Health System and the Icahn
School of Medicine at Mount Sinai
An Innovation Hub presentation at the ATS 2024 International
Conference. This presentation is sponsored by Chiesi and is open to
all ATS 2024 International Conference attendees.
To learn more about Chiesi and our ongoing clinical trials, visit us at Booth #CT12.
USMA-US -TBW-00041
http://www.thoracic.org https://www.chiesiusa.com/
2024 ATS Conference News Preview

Table of Contents for the Digital Edition of 2024 ATS Conference News Preview
